BEYOND STATINS: ADVANCES IN CVD RISK REDUCTION

The Post MI Patient:
A GP’s practical guide to lipid lowering, PCSK9 inhibition and Repatha® (evolocumab)

GP INITIATION OF REPATHA® IS COMING SOON!
The PBAC recently recommended GP initiation of Repatha®, in consultation with a
specialist physician – update to the PBS listing is pending.1
Attend a meeting to prepare for the PBS listing change, enabling you to add
Repatha® to your suite of lipid-lowering therapies.
Meeting objectives include:
• Refresh on managing high-risk atherosclerotic cardiovascular disease (ASCVD) patients
• Revisit the importance of treating lipids to target for CV risk reduction
• Learn about Repatha® – indications, safety, efficacy, dosing and administration
• Understand how to access Repatha® on the PBS
Register at:
amgen.cventevents.com/beyondstatins2022